eyenovia-logo 3

Ram Palanki, Pharm. D.



Ram Palanki, Pharm. D.

Independent Board Member
Dr. Ram Palanki currently serves as Executive Vice President of Commercial Strategy & Operations at REGENXBIO (NASDQ: RGNX), a leader in AAV gene therapy, and is responsible for the planning, execution, and commercialization of their pipeline across the ophthalmology, central nervous system, and neuromuscular disease franchises.

Dr. Palanki has nearly 20 years of experience in the development and commercialization of biopharmaceuticals and medical devices. Before joining REGENXBIO, Dr. Palanki was Senior Vice President of Commercial for the Americas at Santen Inc. Previously, he served as the executive team member leading the strategy and operations for pre-launch and global commercialization of a first-in-class biologic at ThromboGenics (now known as Oxurion, NASDAQ: OXUR). Over the span of his career, Dr. Palanki has held roles of increasing responsibility at several small, mid-sized and large companies, including the launch of LUCENTISĀ® at Genentech. He is an active board member and strategic advisor to multiple biotech companies, technology start-ups and global non-profits.

Ram holds a PharmD from Albany College of Pharmacy, Union University, NY, and his post doctorate from Rutgers University, NJ.